Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Diabetes (Dec 2017)

Posted by Matt Breese on Dec 31, 2017

Find me on:

According to our recent payer coverage analysis for type 2 diabetes treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: Over the past quarter, the diabetes coverage landscape remained stable. Copay tier and utilization management policies are the biggest differentiators between products. This requires increased attention from pharma managed markets team to understand specific brand-by-brand advantages.


MMIT data current as of Q4 2017 

Trends: Recent research reveals some prescriber trends in the market. One trend is the examination of metformin prescribing habits. Market events over the past couple of years, like product launches and products being pulled from the market, forge a dynamic coverage landscape, with heavyweight payer contracting from manufacturers constantly evolving.

To read the full Reality Check on diabetes treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Branding & Marketing